Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
115M
-
Number of holders
-
181
-
Total 13F shares, excl. options
-
74.8M
-
Shares change
-
-1.57M
-
Total reported value, excl. options
-
$1.2B
-
Value change
-
-$20.6M
-
Put/Call ratio
-
1.2
-
Number of buys
-
69
-
Number of sells
-
-94
-
Price
-
$16.07
Significant Holders of Coherus Oncology, Inc. - Common Stock (CHRS) as of Q3 2021
212 filings reported holding CHRS - Coherus Oncology, Inc. - Common Stock as of Q3 2021.
Coherus Oncology, Inc. - Common Stock (CHRS) has 181 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 74.8M shares
of 115M outstanding shares and own 64.84% of the company stock.
Largest 10 shareholders include BlackRock Inc. (11.6M shares), Temasek Holdings (Private) Ltd (7.38M shares), JPMORGAN CHASE & CO (7.17M shares), PERCEPTIVE ADVISORS LLC (4.78M shares), ALLIANCEBERNSTEIN L.P. (4.59M shares), VANGUARD GROUP INC (4.51M shares), STATE STREET CORP (4.03M shares), Kohlberg Kravis Roberts & Co. L.P. (3.04M shares), Aristotle Capital Boston, LLC (2.16M shares), and AMERIPRISE FINANCIAL INC (1.39M shares).
This table shows the top 181 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.